The safety profile of CAMZYOS was evaluated in the Phase 3 EXPLORER-HCM and VALOR-HCM trials across a total of 179 patients with symptomatic obstructive HCM.1–3 The median treatment duration for patients receiving CAMZYOS was 30.1 weeks (range: 1.6–40.3 weeks).1
CAMZYOS (mavacamten) was generally well tolerated across two Phase 3 trials in patients with symptomatic obstructive HCM1–3